Saturday, 2 July, 2022
HomeHepatology

Hepatology

Microbiome analysis to accurately diagnose liver disease

A US research team has developed an algorithm that by analysing stool samples quickly and inexpensively identifies liver fibrosis and cirrhosis over 90% of the...

Large Karolinska study: Successive blood tests to predict liver cirrhosis risk

Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a...

Novel antisense drug shows promise in slowing fatty liver disease

Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San Diego School of...

MAFLD: A new name and definition bringing hope for patients with fatty liver disease

An international consensus panel led by researchers from The Westmead Institute for Medical Research (WIMR) has highlighted the need to redefine Non-Alcoholic Fatty Liver...

Walking and strength training may decrease cirrhosis mortality risk

Physical activity, including walking and muscle-strengthening activities, were associated with significantly reduced risk of cirrhosis-related death, according to research presented at Digestive Disease Week®...

Quick test developed to detect liver damage

Researchers have developed a 'quick and robust' blood test that can detect liver damage before symptoms appear, offering what they hope is a significant...

Faecal transplant produces sustained improvements in cognitive and clinical outcomes

A single treatment using an optimised, targeted form of faecal microbiota transplantation (FMT) produces sustained clinical and cognitive improvements, according to the results of...

Low-cost jaundice detector passes first trial in Africa

BiliSpec a low-cost, battery-powered reader designed to diagnose jaundice by immediately quantifying serum bilirubin levels from a small drop of whole blood, has successfully...

Daily aspirin reduces hep B virus-related liver cancer risk

Daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer, found a study presented this at The Liver...

Impact of behavioural factors on health and survival of HIV-HCV patients

Novel five-year study highlights importance of behaviours such as coffee drinking and not smoking on health and survival of HIV and HCV infected patients,...

Gut microbiome used to predict advanced NAFLD

The unique microbial makeup of a patient's stool sample can be used to predict advanced nonalcoholic fatty liver disease (NAFLD) with 88% to 94%...

High BMI young men face increased liver disease risk later

A high body mass index (BMI) in late adolescent men was associated with an increased risk of future severe liver disease, including hepatocellular carcinoma...

Statins found to help in treatment of chronic liver disease

Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease. In a review of more than 50 studies,...

Blood test predicts best therapy in HCV

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy.

Combination drug success with HCV genotype 1

In two studies, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis, achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of direct-acting-antiviral drugs.

High HCV rate in African HIV patients

In the largest study of its kind to date, researchers found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

HCV combination therapies show promise

A number of new HCV combination therapies show promise.

Potential cure for HBV

Australian scientists have found a potential cure for hepatitis B virus (HBV) infections, with a promising new treatment proving 100% successful in eliminating the infection in pre-clinical models.

New HCV treatment guidelines

The European Association for the Study of the Liver (EASL) has released its latest hepatitis C treatment guidelines.

HBV vaccination must be expanded

The universal infant hepatitis B virus (HBV) vaccination needs further expansion to significantly reduce HBV transmission and liver disease mortality, according to an Imperial College London analysis.

NASH has 50% higher death rate than NAFLD

A population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

In-patient cirrhosis deaths plummet

The largest US sampling to date found 'dramatic improvements' in the survival of patients with cirrhosis and liver failure.

NAFLD promotes coronary artery calcification

Non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

HCV increases cancer risk 'significantly'

Cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort.

Study to look at new ARV tx for HCV

The US National Institutes of Health has launched a clinical trial to examine whether primary care physicians, nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection alone, or co-infected with HIV.

Immunosuppressants may re-activate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a Saint Louis University study.

Erectile dysfunction drugs to treat liver sepsis

Drugs to treat erectile dysfunction might be able to protect the liver from damage caused by sepsis, according to University of Pittsburgh researchers on mice.

Study reverses thought on cirrhotic patients with type 2 diabetes

Researchers at Mayo Clinic have released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. News-Medical reports...